Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044–60.

Article  PubMed  PubMed Central  Google Scholar 

Gavas S, Quazi S, Karpiński TM. Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021;16(1):173.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lv B, Wang Y, Ma D, et al. Immunotherapy: Reshape the Tumor Immune Microenvironment. Front Immunol. 2022;13:844142.

Article  PubMed  PubMed Central  Google Scholar 

Bernstock JD, Kang KD, Klinger NV, et al. Targeting oncometabolism to maximize immunotherapy in malignant brain tumors. Oncogene. 2022;41(19):2663–71.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Donisi C, Pretta A, Pusceddu V, et al. Immunotherapy and Cancer: The Multi-Omics Perspective. Int J Mol Sci. 2024 ;25(6). https://doi.org/10.3390/ijms25063563.

Yu Y, Zeng D, Ou Q, et al. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. JAMA Netw Open. 2019;2(7): e196879.

Article  PubMed  PubMed Central  Google Scholar 

Shimozaki K, Nakayama I, Hirota T, et al. Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era. Cells. 2023;12(7). https://doi.org/10.3390/cells12071049.

Pan C, Liu H, Robins E, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13(1):29.

Article  PubMed  PubMed Central  Google Scholar 

Salvagno C, Mandula JK, Rodriguez PC, et al. Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity. Trends Cancer. 2022;8(11):930–43.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol. 2016;28(8):383–91.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jafarzadeh A, Jafarzadeh Z, Nemati M, et al. The Interplay Between Helicobacter pylori and Suppressors of Cytokine Signaling (SOCS) Molecules in the Development of Gastric Cancer and Induction of Immune Response. Helicobacter. 2024;29(3):e13105.

Article  PubMed  CAS  Google Scholar 

Morelli M, Madonna S, Albanesi C. SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation. Front Immunol. 2024;15:1393799.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tian N, Cheng H, Du Y, et al. Cannabinoid receptor 2 selective agonist alleviates systemic sclerosis by inhibiting Th2 differentiation through JAK/SOCS3 signaling. J Autoimmun. 2024;147:103233.

Article  PubMed  CAS  Google Scholar 

Bidgood GM, Keating N, Doggett K, et al. SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity. Front Immunol. 2024;15:1419951.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dai L, Han Y, Yang Z, et al. Identification and validation of SOCS1/2/3/4 as potential prognostic biomarkers and correlate with immune infiltration in glioblastoma. J Cell Mol Med. 2023;27(15):2194–214.

Article  PubMed  PubMed Central  CAS  Google Scholar 

La Manna S, Lopez-sanz L, Mercurio FA, et al. Chimeric Peptidomimetics of SOCS 3 Able to Interact with JAK2 as Anti-inflammatory Compounds. ACS Med Chem Lett. 2020;11(5):615–23.

Article  PubMed  PubMed Central  Google Scholar 

Elliott J, Suessmuth Y, Scott LM, et al. SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica. 2009;94(4):576–80.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hou Q, Li C, Chong Y, et al. Comprehensive single-cell and bulk transcriptomic analyses to develop an NK cell-derived gene signature for prognostic assessment and precision medicine in breast cancer. Front Immunol. 2024;15:1460607.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li X, Yang Z, Chen B, et al. SOCS3 as a potential driver of lung metastasis in colon cancer patients. Front Immunol. 2023;14:1088542.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zheng X, Shao J, Wei S, et al. Prognostic Significance of SOCS3 in Patients With Solid Tumors: A Meta-Analysis. Front Surg. 2021;8:802143.

Article  PubMed  Google Scholar 

Zhang P, Pei B, Yi C, et al. The role of suppressor of cytokine signaling 3 in inflammatory bowel disease and its associated colorectal cancer. Biochim Biophys Acta Mol Basis Dis. 2025;1871(2):167578.

Article  PubMed  CAS  Google Scholar 

Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387(6636):917–21.

Article  PubMed  CAS  Google Scholar 

Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. Embo j. 1995;14(12):2816–26.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hilton DJ, Richardson RT, Alexander WS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A. 1998;95(1):114–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nicholson SE, Hilton DJ. The SOCS proteins: a new family of negative regulators of signal transduction. J Leukoc Biol. 1998;63(6):665–8.

Article  PubMed  CAS  Google Scholar 

Zhou X, Jiang Z, Zou Y, et al. Role of SOCS3 in the Jak/stat3 pathway in the human placenta: different mechanisms for preterm and term labor. Acta Obstet Gynecol Scand. 2015;94(10):1112–7.

Article  PubMed  CAS  Google Scholar 

Bergamin E, Wu J, Hubbard SR. Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3. Structure. 2006;14(8):1285–92.

Article  PubMed  CAS  Google Scholar 

Funakoshi-tago M, Tsuruya R, Ueda F, et al. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant. Cytokine. 2019;123:154753.

Article  PubMed  CAS  Google Scholar 

Babon JJ, Mcmanus EJ, Yao S, et al. The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Mol Cell. 2006;22(2):205–16.

Article  PubMed  CAS  Google Scholar 

Tamiya T, Kashiwagi I, Takahashi R, et al. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol. 2011;31(5):980–5.